Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.
European Commission, Joint Research Centre (JRC), Ispra, Italy.
J Control Release. 2024 Mar;367:385-401. doi: 10.1016/j.jconrel.2024.01.037. Epub 2024 Feb 1.
The availability of analytical methods for the characterization of lipid nanoparticles (LNPs) for in-vivo intracellular delivery of nucleic acids is critical for the fast development of innovative RNA therapies. In this study, analytical protocols to measure (i) chemical composition, (ii) drug loading, (iii) particle size, concentration, and stability as well as (iv) structure and morphology were evaluated and compared based on a comprehensive characterization strategy linking key physical and chemical properties to in-vitro efficacy and toxicity. Furthermore, the measurement protocols were assessed either by testing the reproducibility and robustness of the same technique in different laboratories, or by a correlative approach, comparing measurement results of the same attribute with orthogonal techniques. The characterization strategy and the analytical measurements described here will have an important role during formulation development and in determining robust quality attributes ultimately supporting the quality assessment of these innovative RNA therapeutics.
用于体内递核酸的脂质纳米粒(LNPs)的分析方法的可用性对于创新 RNA 疗法的快速发展至关重要。在这项研究中,基于将关键物理和化学性质与体外功效和毒性联系起来的综合表征策略,评估和比较了测量(i)化学组成、(ii)药物载量、(iii)粒径、浓度和稳定性以及(iv)结构和形态的分析方案。此外,通过在不同实验室测试同一技术的重现性和稳健性,或者通过相关方法,比较同一属性的测量结果与正交技术,对测量方案进行了评估。这里描述的表征策略和分析测量在制剂开发过程中以及确定稳健的质量属性方面将发挥重要作用,最终支持这些创新 RNA 疗法的质量评估。